Change is blowing through DJO Global, after the medical device company announced plans this summer to relocate from San Diego to Texas. Then came news on Nov. 19 that DJO was acquired for $3.15 billion.
Cibus – a San Diego company that uses gene editing to select desirable plant traits – is seeking $100 million through an initial public offering.
Elliot Ehrich, previously with Alkermes Plc, is the new chief medical officer of San Diego biotech startup Expansion Therapeutics.
Employment in the life sciences sector in San Diego County rose 15.4 percent year over year, according to a recent report.
Arena Pharmaceuticals on Nov. 15 announced a drug licensing deal that provides the company with ample cash to devote to other medicines in its pipeline.
Japan sticks out as San Diego biotech’s most valuable international trading partner. Elsewhere in Asia, regional biotechs like Tocagen are gaining a foothold in China through partnerships with Chinese firms.
StemGenex Biologic Laboratories recently drew a warning letter from the U.S. Food and Drug Administration over manufacturing practices and the marketing of an unapproved stem cell therapy.
With a pipeline that activates tumor-fighting immune cells, Synthorx looks to raise $100 million through an initial public offering.
The San Diego-based company recently experienced growth in its Japanese clientele, which includes several large pharmaceuticals.
Kaer Biotherapeutics of Escondido received a $2 million grant from the National Institutes of Health to help develop a device for people who can't breathe.
San Diego-based Heron Therapeutics recently reported a quarterly loss of $38.3 million, or 49 cents per share.
HEALTH: Region Has Talent, Grants, And Track Record for Fight
In a race to combat antibiotic resistance, big pharma bailed. Investors are skeptical. But Forge Therapeutics isn’t deterred.
San Diego medical device startup Triple W was honored by CES for its wearable device intended to help users with urinary incontinence.
GOVERNMENT: From Reimbursement to Education, Efforts Made
Samumed has yet to put a drug on the market, but the company wants the ear of osteoarthritis policymakers and advocacy groups.